Estrogen receptor enhances the antiproliferative effects of trichostatin A and HC-toxin in human breast cancer cells

被引:8
|
作者
Min, KN [1 ]
Cho, MJ [1 ]
Kim, DK [1 ]
Sheen, YY [1 ]
机构
[1] Ewha Womans Univ, Coll Pharm, Seoul 120750, South Korea
关键词
MCF-7; MDA-MB-468; human breast cancer cell; estrogen receptor; trichostatin A; HC-toxin; HDAC;
D O I
10.1007/BF02980131
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Trichostatin A, an antifungal antibiotics, and HC-toxin are potent and specific inhibitors of histone deacetylase activity. Histone deacetylase inhibitors are new class of chemotherapeutic drugs able to induce tumor cell apoptosis and/or cell cycle arrest. In this study, the antiproliferative activities of trichostatin A and HC-toxin were compared between estrogen receptor positive human breast cancer cell MCF-7 and estrogen receptor negative human breast cancer cell MDA-MB-468. Trichostatin A and HC-toxin showed potent anti proliferative activity in both MCF-7 and MDA-MB-468 cells. In MCF-7 cells that contain high level estrogen receptor, trichostatin A and HC-toxin brought about three-times more potent cell growth inhibitory effect than estrogen receptor negative MDA-MB-468 cells. Both trichostatin A and HC-toxin showed cell cycle arrest at G(2)/M phases of MCF-7 and MDA-MB-468 cells in a dose- and time-dependent manner. Trichostatin A and HC-toxin also induced apoptosis from MCF-7 and MDA-MB-468 cells in a dose- and time-dependent manner. Results of this study suggested that antiproliferative effects of trichostatin A and HC-toxin might be involved in estrogen receptor signaling pathway, but cell cycle arrest and apoptosis of trichostatin A and HC-toxin might not be involved in estrogen receptor system of human breast cancer cells.
引用
收藏
页码:554 / 561
页数:8
相关论文
共 50 条
  • [41] EFFECTS OF ESTROGEN ON HUMAN-BREAST CANCER-CELLS IN CULTURE
    DARBRE, PD
    DALY, RJ
    PROCEEDINGS OF THE ROYAL SOCIETY OF EDINBURGH SECTION B-BIOLOGICAL SCIENCES, 1989, 95 : 119 - 132
  • [42] Trichostatin A and decitabine reverses resistance to docetaxel in human breast cancer cells
    Kastl, L.
    Brown, I.
    Schofield, A. C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 92 - 92
  • [43] Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells
    Chen, Chun
    Baumann, William T.
    Clarke, Robert
    Tyson, John J.
    FEBS LETTERS, 2013, 587 (20) : 3327 - 3334
  • [44] Hispolon inhibits the growth of estrogen receptor positive human breast cancer cells through modulation of estrogen receptor alpha
    Jang, Eun Hyang
    Jang, Soon Young
    Cho, In-Hye
    Hong, Darong
    Jung, Bom
    Park, Min-Ju
    Kim, Jong-Ho
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 463 (04) : 917 - 922
  • [45] Celastrol inhibits the growth of estrogen positive human breast cancer cells through modulation of estrogen receptor α
    Jang, Soon Young
    Jang, Sung-Wuk
    Ko, Jesang
    CANCER LETTERS, 2011, 300 (01) : 57 - 65
  • [46] Effects of triclocarban on the transcription of estrogen, androgen and aryl hydrocarbon receptor responsive genes in human breast cancer cells
    Tarnow, Patrick
    Tralau, Tewes
    Hunecke, Danele
    Luch, Andreas
    TOXICOLOGY IN VITRO, 2013, 27 (05) : 1467 - 1475
  • [47] Effects of pyrethroid compounds on alkaline phosphatase activity in estrogen receptor positive human breast cancer cells.
    Kim, I
    TOXICOLOGICAL SCIENCES, 2003, 72 : 90 - 90
  • [48] Different anticancer effects of Saxifragifolin A on estrogen receptor-positive and estrogen receptor-negative breast cancer cells
    Kim, Kyung-Ho
    Kim, Ji-Yun
    Kwak, Jong-Hwan
    Pyo, Suhkneung
    PHYTOMEDICINE, 2015, 22 (09) : 820 - 828
  • [49] Impact of estrogen receptor β on gene networks regulated by estrogen receptor α in breast cancer cells
    Chang, Edmund C.
    Frasor, Jonna
    Komm, Barry
    Katzenellenbogen, Benita S.
    ENDOCRINOLOGY, 2006, 147 (10) : 4831 - 4842
  • [50] Estrogen receptor corepressors - a role in human breast cancer?
    Dobrzycka, KM
    Townson, SM
    Jiang, S
    Oesterreich, S
    ENDOCRINE-RELATED CANCER, 2003, 10 (04) : 517 - 536